Cefpirome Sulphate

N/A

Cefpirome is indicated in: Severe infections, such as septicemia, bacteremia and infections in immunosuppressed neutropenic patients with hematological malignancies Lower respiratory infections including pneumonia Severe urinary tract infections including pyelonephritis Skin and soft tissue infections ... Read moreCefpirome is indicated in: Severe infections, such as septicemia, bacteremia and infections in immunosuppressed neutropenic patients with hematological malignancies Lower respiratory infections including pneumonia Severe urinary tract infections including pyelonephritis Skin and soft tissue infections Bone and joint infections Infections in immunocompromised patients Other infections

N/A

Cefpirome is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Cefpirome binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.

Drug interactions have not been observed with Cefpirome.

Cefpirome is generally well tolerated. There are no predictable life threatening effects of Cefpirome. Adverse gastrointestinal reactions include diarrhea, nausea, vomiting, pseudomembraneous colitis, abdominal pain and have been noted 3.86% of the patients. Superficial phlebitis, thrombophlebitis and infection site reaction have been reported in 2.31% of patients receiving intravenous Cefpirome.

No cases of over dosage are known. However, general supportive care with monitoring of renal, hematological and hepatic function and coagulation status is recommended.

The safety of Cefpirome has not been established in pregnancy and as with all agents it should be administered with caution, especially during the early months of pregnancy. As Cefpirome is excreted in human breast milk, either Cefpirome treatment should be discontinued or breast feeding ceased.

Allergy to penicillin or to cephalosporins; renal impairment, monitor renal and haematological status; pregnancy and lactation.

The duration of treatment depends on the patient’s clinical and bacteriological response.